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ABSTRACT
Objective: In an automated dose dispensing (ADD) service, medicines are dispensed in unit-
dose bags according to administration times. When the service is initiated, the patient’s medica-
tion list is reconciled and a prescription review is conducted. The service is expected to reduce
drug use. The aim of this national controlled study was to investigate whether the ADD service
with medication review reduces drug use among geriatric primary care patients.
Design, setting and patients: This is a nationwide cohort study with matched controls. The
study group consisted of all primary care patients 65 years enrolled in the ADD service in
Finland during 2007 (n¼ 2073). Control patients (n¼ 2073) were matched by gender, age, area
of patient’s residence and number of the prescription drugs reimbursed. The data on all pre-
scription drugs reimbursed during the 1 year periods before and after the ADD service enroll-
ment were extracted from the Finnish National Prescription Register. Drug use was calculated as
defined daily doses (DDD) per day.
Results: The studied 20 most used drugs covered 86% of all reimbursed drug use (in DDD) of
the study group. The use of 11 out of these 20 active substances studied was reduced signifi-
cantly (p< .001–.041) when the drug use was adjusted by the number of chronic diseases. Two
of these drugs were hypnotics and six were cardiovascular system drugs.
Conclusions: Drug use was decreased after initiation of the ADD service in primary care patients
65 years compared to matched controls in this 1 year cohort study. Further studies should be
conducted in order to explore the causality, assess the ADD service’s impact on drug use quality
and costs, as well as impact of accompanied prescription review on positive outcomes.
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1. Introduction
Achieving appropriate and safe medication use is chal-
lenging among elderly primary care patients [1,2].
Interventions, such as different types of medication
reviews, have been developed to identify, solve and
prevent drug-related problems among these patients
[3–5]. In some countries community pharmacies pro-
vide an automated dose dispensing (ADD) service for
primary care patients [6]. In this service, medicines are
dispensed in unit-dose bags according to administra-
tion times [7]. The service is rather widely used, in
2011 in Sweden there were 190,000 patients using the
service while in the Netherlands there were 360,000
users in 2011 [8,9]. At the end of 2016, the number of
patients in Finland was 49,500 and it is increasing
(unpublished data received from the Social Insurance
Institution).
Although ADD is used quite commonly for geriatric
patients with multiple morbidities and medications, lit-
tle is known of ADD’s impact on patients medication
use. A systematic review showed that no controlled
studies have assessed its outcomes [6]. The systematic
review showed that patients using the ADD service
have more potentially inappropriate drugs in their reg-
imens than patients using the standard dispensing
procedure, which is in line with the idea of ADD per-
forming as a preventive procedure for medication risks
[6,10,11]. However, the impact of the ADD service on
inappropriate drug use has not been evaluated, since
the studies have applied cross-sectional study designs.
A study from Norway revealed that ADD may improve
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medication safety in terms of reconciling medication
records [12]. There is also some evidence that patients
may benefit if their medications are reviewed as part
of the ADD procedure [13]. The aim of this national
controlled study was to investigate associations
between the ADD service with medication review and
drug use in the elderly. Our hypothesis was that intro-
duction of the ADD service was followed by a reduc-
tion in drug use among geriatric primary care patients
in Finland.
2. Methods
2.1 Study design
This study was a register-based cohort study with
matched controls. The control patients were matched
by gender, age, area of patient’s residence and num-
ber of prescription drugs used. These parameters were
selected because these issues commonly affect drug
use and confounding could be avoided by matching
in a cohort study [14].
2.2 Intervention
In the ADD service, the patient’s regularly used medi-
cines are packed by a machine in plastic unit-dose
bags according to the time of administration [6,7].
Each unit-dose bag is labeled with the patient’s data,
drug contents and administration time. When the ADD
service is initiated for an individual patient, the
patient’s medication list is reconciled and the medica-
tion is reviewed in collaboration with a physician and
a community pharmacist [7]. When the data for this
study were collected in 2007, there was one commu-
nity pharmacy (Espoonlahti Pharmacy, Espoo, Finland)
specialized in preparing unit-dose bags for national
demand. Other community pharmacies could make a
contract with it for procuring unit-dose bags for their
customers.
2.3 Patients and data sources
The study group consisted of all primary care patients
who were 65 years and were enrolled in the ADD
service in 2007 in Finland and used the service at least
1 year after the start-up date. The patients enrolled in
the ADD service were extracted from the customer
register of Espoonlahti Pharmacy. For each patient in
the study group, a control patient was selected indi-
vidually from the registers of the Social Insurance
Institution by the personnel of the institution in June
2011. They were matched by gender, age (at the end
of the year), area of patient’s residence (hospital dis-
trict) and the exact number of prescription drugs reim-
bursed during the period August–November in 2006.
The number of prescription drugs reimbursed was cal-
culated using the Anatomic Therapeutic classification
(ATC) system’s 5th level [15]. The start-up date of the
ADD service was used as an index date for both the
control and study patients.
The data on all prescriptions reimbursed during the
1 year periods before and after initiation of the ADD
service were extracted from the Finnish National
Prescription Register for each patient in the study and
control groups [16]. This register contains information
on all reimbursed prescriptions for outpatients. Every
patient has a personal identification (ID) number that
was used to link the data from the customer register
of Espoonlahti Pharmacy with the prescription data.
Patients who had no drug purchases in the register
before the ADD service was initiated (n¼ 34) were
omitted since this might indicate, that they have been
living in an institution and their drug use might have
been quite different compared to patients living at
home. Also patients who had manually dose dispensed
drug purchases before the ADD service was initiated
(n¼ 37) were omitted since our aim was to study drug
use in automatic dose dispensing (Figure 1). If a
matched control patient was not found, the patient
was removed from the study group (n¼ 67). As the
aim was to study the elderly population, patients
younger than 65 years were excluded from the study
and control groups.
The data on all chronic diseases for the study and
control patients were extracted from the Special
Reimbursement Entitlement Register, which is also
maintained by the Social Insurance Institution [17].
2.4 Outcome measures and definitions
Drug use was calculated as defined daily doses per
day (DDD/day) by active substance derived from ATC
fifth level [15,18]. Drug use was calculated separately
for each patient in the study and control groups dur-
ing the 1 year periods before and after initiation of the
ADD service. For each patient, the first and last pur-
chase dates of each drug (by ATC code) were recog-
nized. The number of days between these two time
points was counted. The sum of the DDDs was
counted from the first purchase point until the second
last purchase point. The number of DDDs of the last
purchase point was not counted in the sum since we
could not predict the duration of drug use because
the following purchase date was not known. The sum
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of the DDDs was divided by the sum of the days to
obtain DDD/day values.
A patient was assumed to be a new drug user if
he/she had no purchases of a certain drug in the
1 year period before ADD but there was at least one
purchase in the 1 year period after the ADD service
was initiated. If the patient had no purchases of a cer-
tain drug for 1 year after the ADD service was initiated
but there was at least one purchase during the 1 year
period before ADD, the drug use was assumed as
discontinued.
The 20 most used drugs (in DDDs) in the 2 year
study period were chosen for the analysis. These 20
drugs covered 86% of all reimbursed drug use (in
DDD) of the study group.
2.5 Statistical analysis
The mean drug use in DDD/day was tested with the
general linear model, using repeated measures ana-
lysis. The p values for group, time and timegroup
effects were calculated. The group effect compares the
drug use of the study and control groups (not taking
into account the initiation of the ADD service). The
time effect compares the drug use before and after
the initiation of the ADD service (not taking into
account the study and control groups). The time-
group takes account both of these aspects. The num-
ber of chronic diseases was used as a covariate in the
analysis. After fitting the model, outliers in the values
of the drug use were checked individually from the
original register data. In 10 cases, the values of the
drug use were removed from the data, due to an
apparent error in the original register data. The differ-
ences between the proportions of the patients who
started and discontinued the drug use in the study
and control groups were tested with the Pearson’s chi-
squared test.
All tests were carried out with SPSS version 18.0 for
Mac (IBM SPSS, Armonk, NY). A difference was consid-
ered statistically significant if the p value was less
than .05.
2.6 Ethical approval
The University of Helsinki Viikki Campus Ethics
Committee approved the study protocol.
3. Results
3.1 Characteristics of the study and control
groups
The total number of patients in both the study and
control groups was 2073 (Figure 1, Table 1). A majority
of the patients in both groups were female (73%).
Most of the patients (85%) were >75 years of age, the
mean age being 82 (SD 6.9) years. The mean number of
reimbursed prescription drugs used during the 4month
period before the study period was 6.5 (SD 3.5).
The study and control groups were different in
terms of chronic diseases (Table 2). The proportions of
No drug purchases
before ADD, n=34
Manually dose
dispensed drug
purchases before ADD,
n=37
Matching
Study group
n=2300
Study group
n=2367
Study group
n=2438
No control patients
found, n=67
Patients < 65 years
removed, n=227
Study group
n=2073
Matched
control group
n=2073
Matched
control group
n=2300
Matched
control group
n=2300
Patients < 65 years
removed, n=227
Figure 1. Patients selection process.
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the patients suffering from Alzheimer’s disease, dia-
betes, severe psychotic or other severe mental disor-
ders, Parkinson’s disease and epilepsy were higher in
the study than in the control group. The contrasting
relationship prevailed for dyslipidemia, glaucoma and
chronic asthma or other chronic obstructive pulmonary
diseases.
3.2 Drug use
In 11 of the 20 most-used active substances studied,
the reduction in drug use in the study group was stat-
istically significant when both the time and group
effects were taken into account in the analysis, and
the drug use was adjusted by the number of chronic
diseases (Table 3). Two of these substances were
hypnotics (temazepam and zopiclone), six were drugs
for cardiovascular diseases (simvastatin, ramipril, amlo-
dipine, isosorbide mononitrate, bisoprolol and meto-
prolol) and the others were donepezil (used for
Alzheimer’s disease), paracetamol (used for pain) and
metformin (used for diabetes).
3.3 Patients who started and discontinued drug
use
There were more starts and discontinuations in the
study group than in the control group during the fol-
low-up period (Table 4). The zopiclone, temazepam
and calcium combinations were more actively started
and discontinued in the study group. Glimepiride and
metoprolol were more actively started, while isosor-
bide mononitrate was more actively discontinued in
the study group.
4. Discussion
To our knowledge, this is the first nationwide con-
trolled study on the influence of ADD on drug use in
primary care patients. The study findings suggest that
ADD decreased drug use in a 1 year observation
period. The decrease was found in more than half of
the top 20 active substances used. Two of these drugs,
temazepam and zopiclone, are potentially inappropri-
ate hypnotics for geriatric patients [19]. ADD service
patients also had more starts and discontinuations in
their drug use than matched control patients.
The decrease in drug use may be related to two of
the ADD service’s characteristics, a prescription review
conducted and reduced amount of the drug wastage.
First, the ADD procedure in Finland includes a pre-
scription review for each patient before the enroll-
ment. At minimum, doses, duplications and drug–drug
interactions are checked during the prescription review
[7]. As a consequence, this may lead to reduction in
drug use, as suggested by our findings. If the medica-
tion review is properly conducted, it should also lead
to qualitative changes in the individual patient’s medi-
cations in those cases with potentially inappropriate
medications. In our study, the changes in drug use
quality were indicated by the fact that hypnotic use
was more often started and discontinued in the ADD
service group. The daily doses of zopiclone and tem-
azepam were also reduced. They are both medicines
that should be avoided or at least their use should be
limited to a minimum in older people, due to their
short-term and long-term adverse effects [19,20].
Table 2. Prevalence of diagnosed chronic diseases in the
study (n¼ 2073) and control (n¼ 2073) groups.
Diagnosed disease (in late 2006) Study % (n) Control % (n)
Chronic heart or cardiovascular disease 59.9 (1242) 62.4 (1293)
Alzheimer’s disease 24.4 (506) 6.5 (134)
Diabetes mellitus 19.2 (399) 16.6 (344)
Dyslipidemia 10.0 (207) 12.7 (263)
Severe psychosis and other severe
mental disorders
9.4 (195) 2.4 (50)
Glaucoma 9.2 (190) 12.5 (260)
Chronic asthma or other chronic
obstructive pulmonary diseases
9.2 (190) 11.9 (247)
Thyroid insufficiency 6.4 (132) 6.8 (141)
Disseminated connective tissue diseases,
rheumatoid arthritis, and
comparable conditions
5.6 (117) 5.0 (103)
Parkinson’s disease 4.0 (82) 1.6 (33)
Epilepsy 3.0 (62) 1.3 (27)
Cancer 3.0 (62) 3.9 (81)
Other diseases 7.2 (149) 6.8 (140)
Table 1. Matching criteria of the study (n¼ 2073) and control
(n¼ 2073) groups. The composition of both groups is pre-
sented in the same column, since the groups were similar.
Variable Study and control % (n)
Gender
Female 73 (1522)
Male 27 (551)
Age, yearsa
Median (years) 81.9
Mean (years) 82 (SD 6.9)
65–74 15 (311)
75–84 48 (988)
85–94 35 (731)
95–103 2 (43)
Patients’ area of residence
Capital area 37 (776)
Western Finland 5 (112)
Central Finland 18 (379)
Eastern Finland 19 (392)
Northern Finland 20 (414)
Number of reimbursed prescription
drugs used before automated
dose dispensingb
Median (n) 6
Mean (n) 6.5 (SD 3.5)
ain late 2007.
bduring 4months (August–November 2006).
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Still, they are quite commonly used among older pri-
mary care patients.
Integrating medication reviews as part of the initi-
ation of ADD is also supported by the fact that
patients using ADD may have more inappropriate
drugs in their regimens than patients using the stand-
ard dispensing procedure [10,11]. This can be consid-
ered as a natural consequence of the fact that the
Table 3. Drug use (DDD/day) adjusted by the number of chronic diseases in the study and control groups before and after the
automated dose dispensing (ADD) service was initiated. The 20 most-used (in DDDs) drugs among the study group were chosen
for the analysis.
Active substance (ATC code)
Study group (n¼ 2073) Control group (n¼ 2073) p values
Before
ADD Mean
After
ADD Mean
Before
ADD Mean
After
ADD Mean
Group
effect
Time
effect
Timegroup
effect
Cardiovascular system
Furosemide (C03CA01) 1.69 1.67 1.45 1.57 .121 .488 .060
Ramipril (C09AA05) 2.21 2.04 2.42 2.58 .003 .922 .003
Enalapril (C09AA02) 1.32 1.22 1.53 1.50 .005 .528 .188
Bisoprolol (C07AB07) 0.53 0.42 0.57 0.56 <.001 .002 <.001
Metoprolol (C07AB02) 0.55 0.48 0.57 0.57 .035 .386 <.001
Amlodipine (C08CA01) 1.40 1.16 1.27 1.32 .782 .010 <.001
Isosorbide mononitrate (C01DA14) 0.81 0.67 0.79 0.79 .057 .186 <.001
Simvastatin (C10AA01) 1.27 1.14 1.20 1.28 .511 .097 <.001
Nervous system
Zopiclone (N05CF01) 1.01 0.95 0.97 0.99 .981 .382 .014
Temazepam (N05CD07) 1.02 0.82 1.04 1.03 .015 .032 <.001
Citalopram (N06AB04) 0.88 0.86 0.89 0.90 .623 .449 .624
Mirtazapine (N06AX11) 0.85 0.76 0.71 0.73 .068 .411 .060
Donepezil (N06DA02) 1.15 1.11 1.12 1.21 .475 .045 .021
Memantine (N06DX01) 0.87 0.87 0.87 0.91 .327 .072 .307
Paracetamol (N02BE01) 0.43 0.42 0.37 0.41 .032 .528 .041
Alimentary tract and metabolism
Lactulose (A06AD11) 2.22 2.10 1.76 1.76 .044 .072 .593
Glimepiride (A10BB12) 1.46 1.37 1.62 1.63 .033 .366 .158
Metformin (A10BA02) 0.85 0.81 0.81 0.84 .861 .855 .002
Calcium combinations (A12AX) 0.94 0.82 0.88 0.83 .697 .151 .545
Pantoprazole (A02BC02) 0.76 0.67 0.67 0.65 .064 .012 .059
ATC: anatomic therapeutic classification; ADD: automated dose dispensing; DDD: defined daily dose.
Table 4. Proportions of patients who started and discontinued drug use in the study and control groups. The 20 most-used (in
DDDs) drugs among the study group were chosen for the analysis.
Active substance (ATC-code)
Started drug usea Discontinued drug useb
Study % (n) Control % (n) p valuec Study % (n) Control % (n) p valuec
Cardiovascular system
Furosemide (C03CA01) 17.7 (160) 18.8 (120) .581 5.1 (40) 8.9 (51) .005
Ramipril (C09AA05) 17.5 (48) 20.9 (48) .330 9.9 (25) 13.7 (29) .202
Enalapril (C09AA02) 9.9 (18) 13.9 (28) .225 11.4 (21) 13.9 (28) .447
Bisoprolol (C07AB07) 13.1 (85) 13.8 (95) .720 6.2 (37) 6.8 (43) .677
Metoprolol (C07AB02) 8.5 (35) 4.2 (14) .017 6.2 (25) 9.8 (35) .067
Amlodipine (C08CA01) 18.6 (49) 19.6 (55) .765 14.1 (35) 13.5 (35) .846
Isosorbide mononitrate (C01DA14) 11.9 (48) 10.1(45) .397 9.6 (38) 5.4 (23) .021
Simvastatin (C10AA01) 12.1 (56) 15.7 (88) .103 6.5 (28) 9.6 (50) .080
Nervous system
Zopiclone (N05CF01) 22.1 (94) 14.9 (57) .008 25.6 (114) 18.1 (72) .009
Temazepam (N05CD07) 22.9 (73) 11.2 (25) <.001 23.6 (76) 13.1 (30) .002
Citalopram (N06AB04) 17.2 (59) 21.8 (29) .246 19.3 (68) 22.4 (30) .451
Mirtazapine (N06AX11) 24.6 (73) 31.4 (38) .152 15.2 (40) 25.2 (28) .021
Donepezil (N06DA02) 17.0 (39) 29.5 (18) .029 10.0 (21) 6.5 (3) .469
Memantine (N06DX01) 30.6 (75) 31.3 (21) .909 4.0 (7) 2.1 (1) .548
Paracetamol (N02BE01) 39.0 (316) 43.1 (169) .174 29.5 (207) 35.0 (120) .074
Alimentary tract and metabolism
Lactulose (A06AD11) 40.6 (162) 40.2 (49) .931 28.4 (94) 38.1 (45) .049
Glimepiride (A10BB12) 13.1 (26) 6.1 (11) .014 19.2 (41) 13.8 (27) .143
Metformin (A10BA02) 10.0 (27) 14.0 (38) .159 12.6 (35) 9.7 (25) .274
Calcium combinations (A12AX) 59.8 (297) 38.6 (134) <.001 41.0 (139) 20.8 (56) <.001
Pantoprazole (A02BC02) 28.2 (104) 25.7 (67) .485 23.4 (81) 29.5 (81) .088
ATC: anatomic therapeutic classification; DDD: defined daily dose.
aDrug use was considered as started if patient did not fill any prescriptions for 1 year before ADD but filled at least one prescription for 1 year after ADD
was initiated.
bDrug use was considered discontinued if a patient did not fill any prescriptions for 1 year after ADD initiation but filled at least one prescription for
1 year before ADD was initiated.
cChi-squared test.
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ADD service is planned to aid in managing medica-
tions for patients with multiple medications and
chronic diseases. Thus, those enrolled in the service
have more complex diseases and treatments [6]. This
tendency was also found in our study. However, as
this is a register-based study, it is difficult to interpret
the exact effect of the decrease in drug use on, e.g.
patient functional ability or quality of life. Further stud-
ies should explore ADD’s impact on drug use quality
or patient welfare in more detail. Special focus should
be on assessing the usefulness of medication reviews
as part of the ADD service during the initiation phase
and later.
Another reason for the reduced drug use in the
ADD group may be reduced drug wastage, compared
with the standard dispensing procedure, because in
ADD, drugs are dispensed for a period of 14 days.
Normally in Finland, drugs are dispensed for 3months
in packages of 30 or 100 tablets. If a drug is discontin-
ued for a patient having the ADD service, only a max-
imum of 2weeks’ drug supply is wasted. In the
standard dispensing procedure, the wastage could be
up to 3months’ supply, i.e. six times more.
Starts and discontinuations observed in drug use
may partly be artefacts, rather than actual events.
These are related to the reimbursement system, since
it does not cover all medicines and package sizes. In
ADD, reimbursed medicines are favored. If non-reim-
bursed medicines are dispensed before the ADD ser-
vice initiation and reimbursable medicines after it, this
would appear to indicate a change (initiation) in the
register data. Thus, the register data would be lacking
some of the data needed to evaluate the impact of
the ADD service on the appropriateness of the drug
use. In future studies, the impact of ADD on medica-
tion costs should also be estimated.
4.1 Strengths and limitations of the study
The main strength of this nationwide study is the con-
trolled study design that was applied. Patients’ gender,
age, area of residence and number of drugs dispensed
were used as matching criteria for the study and con-
trol groups. Moreover, the number of patients’ dis-
eases was controlled in the statistical analysis. Another
strength is that the data were collected from the regis-
ter data that cover all reimbursed prescription drug
purchases for primary care patients living in Finland.
All permanent residents of Finland are entitled to have
their drug costs refunded. The reimbursement system
remained the same during the study period of
2006–2008. Thus, drug use changes or changes in
patient proportions starting and discontinuing drug
use could not be explained by fundamental changes
in the reimbursement system.
The register data used in this study were routinely
collected for administrative purposes, and thus, they
do not necessarily represent the actual drug use in pri-
mary care. The data do not include drug use in institu-
tions, over-the-counter drugs and drugs that are not
reimbursed, e.g. small packages of some medicines.
The fact that only reimbursed products were included
in the register could have resembled an increase in
drug use, especially in the study group, since reimbursed
products are favored in ADD. However, this study found
that drug use decreased in the study group.
An important issue that should be remembered
when interpreting the results of this study is that the
patients using the ADD service were a highly selected
patient group. Despite the matching, the prevalence
of chronic diseases was higher in the study than in
the control group. This may be explained by the fact
that ADD patients suffer more often from severe cen-
tral nervous system diseases, leading to complicated
drug combinations [10,11]. Therefore, drug consump-
tion could be expected to be higher in the study than
in the control group, however, drug consumption was
decreased in the study group. In the future studies
exclusion of the Alzheimer’s disease patients and
patients suffering severe mental diseases should be
considered since drug use in this patient group might
be quite different compared patients’ not suffering
these diseases. This exclusion might add reliability of
the results regarding drug use. The patients of the
study and control groups might also be quite different
as users of the healthcare services since there were
more chronic diseases and starts or discontinuations in
their drug use among patients using the ADD service.
A strict matching and exclusion criteria were
applied in the study. For each patient in the study
group one control patient was chosen according
matching criteria. The study group was a selected
patient group and thus controls for all patients were
not found. If a control patient was not found the
patient from the study group was removed. This fact
might cause selection bias in the results. Strict exclu-
sion criteria were also applied in this study. This
caused 15% reduction in the study population. In the
future, it would be useful to study ambulatory care
ADD service in a randomized controlled trial setting.
However, the observational design applied in this
study gives an important contribution to the body of
the ADD research [6]. By matching it was possible to
enhance equal distribution of the variables that might
possibly confound the results regarding the drug
use [14].
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5. Conclusions
Drug use was decreased after initiation of the ADD
service with medication review in primary care
patients 65 years compared to matched controls in
this 1 year cohort study. Further studies should be con-
ducted in order to explore the causality, assess the
ADD service’s impact on drug use quality and costs, as
well as impact of accompanied prescription review on
positive outcomes.
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